![Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5938/TOC-Subject-Sample-2021-Health-Social-Care.jpg"})
ABSTRACT
This study used conjoint analysis, a marketing research technique, to investigate hospital stakeholders’ decision-making in adoption of evidence-based interventions (EBI). An efficacious hospital-based stigma-reduction intervention was used as a ‘product’ to study adoption of EBI. Sixty hospital directors in Fujian, China evaluated the likelihood of adopting the EBI in their hospitals by rating across eight hypothetical scenarios with preferred and non-preferred levels of seven attributes, including (1) administrative support, (2) cost, (3) personnel involvement, (4) format, (5) duration, (6) technical support, and (7) priority alignment with the hospital. A hierarchical generalized linear model was fit to the likelihood of intervention adoption for the eight scenarios, with the seven attributes served as independent variables. Monetary cost of intervention implementation (impact score = 2.12) had the greatest impact on the directors’ reported likelihood of adopting the EBI, followed by duration of the intervention (impact score = 0.88), availability of technical support (impact score = 0.69), and flexibility of format (impact score = 0.36). The impact scores of other attributes were not statistically significant. Conjoint analysis was feasible in modeling hospital directors’ decision-making in adoption of EBI. The findings suggested the importance of considering cost, duration, technical support, and flexibility of format in development and dissemination of interventions in healthcare settings.
Acknowledgements
We would like to thank the project team members in the Fujian Provincial Center for Disease Control and Prevention for their contributions to this study.
Disclosure statement
No potential conflict of interest was reported by the authors.
Additional information
Funding
Notes on contributors
Chunqing Lin
Chunqing Lin, Ph.D., is an Assistant Professor-in-Residence in the Department of Psychiatry and Biobehavioral Sciences at UCLA. She is a Core Scientist in the Methods Core at UCLA Center for HIV Identification, Prevention and Treatment Services (CHIPTS). She has research experience in implementation science and intervention delivery in healthcare settings.
Li Li
Li Li, Ph.D., is a professor at the Department of Psychiatry and Biobehavioral Sciences the Department of Epidemiology, UCLA. She is the Director of the Methods Core of CHIPTS. She has extensive research experiences in the areas of HIV prevention, substance abuse, and social and cultural aspects of health promotion and services.
Sung-Jae Lee
Sung-Jae Lee Ph.D., is an Associate Professor-in-Residence in the Department of Psychiatry and Biobehavioral Sciences, UCLA David Geffen School of Medicine, with a joint appointment in the Department of Epidemiology, UCLA Fielding School of Public Health. His methods expertise includes conjoint analysis to assess consumer preferences in biomedical strategies.
Liang Chen
Liang Chen, MD., M.S., is the Chief of the Behavior Intervention section, HIV/STD Prevention Department, Fujian Center for Disease Control and Prevention (CDC). He has research experiences in HIV epidemiological studies and behavioral prevention.
Yunjiao Pan
Yunjiao Pan, MD., is a Research Scientist in the Behavior Intervention section, HIV/STD Prevention Department, Fujian Center for Disease Control and Prevention (CDC). He has research experiences in HIV epidemiological studies and behavioral prevention.
Jihui Guan
Jihui Guan, MD., is a Senior Researcher in Fujian CDC. She is the former Deputy Director of Fujian CDC and former Director of Fujian Institute of Health Education. She has research experiences in health education and promotion.